title: Comprehensive genomic profiling (CGP) of ovarian clear cell carcinomas (OCCC) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options.
abstract: •MTOR pathway genes are often mutated in ovarian clear cell carcinomas (OCCC).•11.2% of OCCC have targetable alterations only in the mTOR pathway.•MTOR pathway mutations in OCCC can underlie robust, lasting responses to everolimus.
authors.affiliation: Foundation Medicine, Inc., Cambridge, MA, United States.
authors.forename: Julia A
authors.initials: JA
authors.lastname: Elvin
authors.affiliation: Cancer Treatment Centers of America at Eastern Regional Medical Center, Philadelphia, PA, United States.
authors.forename: Justin
authors.initials: J
authors.lastname: Chura
authors.affiliation: Foundation Medicine, Inc., Cambridge, MA, United States.
authors.forename: Laurie M
authors.initials: LM
authors.lastname: Gay
authors.affiliation: Cancer Treatment Centers of America at Eastern Regional Medical Center, Philadelphia, PA, United States.
authors.forename: Maurie
authors.initials: M
authors.lastname: Markman
keywords: Comprehensive genomic profiling; Everolimus; Ovarian clear cell carcinoma; PIK3CA; PTEN